On September 3, 2024, Aimai Vaccine Co., Ltd. submitted the latest monthly report on securities changes to the Hong Kong Exchanges and Clearing Limited, reporting the changes in share capital as of August 31, 2024. The report shows that the number of listed H shares of Aimai Vaccine remains at 492,173,711 shares, while the number of domestic shares remains at 718,888,888 shares, with no increase or decrease this month. In addition, the company's share options program was adopted on November 30, 2020 and revised on February 16, 2022. As of the end of this month, according to the employee share incentive plan before the initial public offering, the number of outstanding share options is 3,141,000 shares. Aimai Vaccine confirms that all securities issuances or sales or transfers of treasury shares have been authorized by the board of directors and comply with relevant listing rules and regulations.

On September 3, 2024, Aimai Vaccine Co., Ltd. submitted the latest monthly report on securities changes to the Hong Kong Exchanges and Clearing Limited, reporting the changes in share capital as of August 31, 2024. The report shows that the number of listed H shares of Aimai Vaccine remains at 492,173,711 shares, while the number of domestic shares remains at 718,888,888 shares, with no increase or decrease this month. In addition, the company's share options program was adopted on November 30, 2020 and revised on February 16, 2022. As of the end of this month, according to the employee share incentive plan before the initial public offering, the number of outstanding share options is 3,141,000 shares. Aimai Vaccine confirms that all securities issuances or sales or transfers of treasury shares have been authorized by the board of directors and comply with relevant listing rules and regulations.